Metformin inhibits 2D and 3D motility in astrocytoma cancer cells. (c2014) by Hassan, Marwa Fouad Al
 
 
LEBANESE AMERICAN UNIVERSITY 
 
Metformin inhibits 2D and 3D motility in Astrocytoma Cancer Cells 
 
By 
Marwa Fouad Al Hassan 
 
 
 
 
A thesis submitted in partial fulfillment of the 
requirements for the degree of Master of Science in 
Molecular Biology 
 
 
 
 
 
School of Arts and Sciences 
May 2014 
 
ii 
 
 
iii 
 
 
iv 
 
 
 
  
v 
 
DEDICATION 
 
 
 
 
 
 
 
 
To my Beloved Parents  
My whole life 
 
 
 
 
 
 
 
 
 
vi 
 
ACKNOWLEDGMENTS 
 
First of all, I would like to extend my greatest and most sincere gratitude to Dr. 
Mirvat El-Sibai who has not only been a supportive advisor but a friend and a role 
model. I’m very grateful for her continuous care, support, and motivation. It was an 
honor to work with such an intelligent and enthusiastic scientist.  
Also, I would like to extend my appreciation to the Interim Dean of Arts and 
Sciences Dr. Nashat Mansour, the Assistant Dean Dr. Sandra Rizk Jamati, Chairperson 
of the Biology department Dr. Costantine Daher, the Associate Chair Dr. Ralph Abi-
Habib, the faculty members of the Biology department Dr. Roy Khalaf, Dr. George El 
Khazen, Dr. Fouad Hashwa, Dr. Sima Tokajian, Dr. Michella Sabbagh, Dr. Brigitte 
Wex, Dr. Pierre Zalloua, and Dr. Ralph Abi-Habib, and to the committee members Dr. 
Sandra Rizk-Jamati and Dr.Roy Khalaf. I also want to thank Ms. Maya Farah and Ms. 
Helena Bou Farah, Ms. Sawsan Jabi, and Ms. Hanan Naccash for their technical support.  
Last but not least, I would like to convey my deepest appreciation and love to my 
great family. I’m so lucky to have great family and friends who were extremely 
supportive. I would like to thank my fiancé, Mr. Mahmoud Ghouzail, for all the support 
he has provided, and for believing in me and in my skills and capabilities.  
 
 
 
vii 
 
Metformin inhibits 2D and 3D motility in Astrocytoma Cancer 
Cells 
 
Marwa F. Al Hassan  
 
ABSTRACT 
 
Metformin is an oral anti-hyperglycemic agent in the biguanide class which 
lowers blood glucose concentrations and has been used to treat type 2 diabetes 
mellitus. Metformin is highly used in polycystic ovary syndrome (PCOS), premature 
puberty, and non-alcoholic fatty liver disease (NAFLD). A brain tumor is an 
intracranial solid neoplasm which is a tumor within the brain or the central spinal 
canal. According to the World Health Organization (WHO), primary brain tumors 
are classified according to their histological characteristics and cellular origin. In 
addition, gliomas, which belong to the neuroepithelial brain tumors, include 
oligodendroglioma, astrocytoma, ependymoma, mixed glioma, and glioblastoma. 
Previous studies showed a cytotoxic effect of metformin on ovarian cells. This 
prompted us, in our current study, to investigate the effect of metformin on the 
proliferation and metastasis astrocytoma. When this drug is applied, it led to a 
relative decrease in the proliferation of astrocytoma cancer cells. Metformin 
treatment also resulted in a drastic inhibition of 2D cell motility and an increase in 
cellular adhesion. Hence, our study shows that Metformin could be used as an anti-
metastatic drug in brain tumor. 
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Chapter I 
LITERATURE REVIEW 
 
1.1. Brain tumors 
1.1.1. Introduction  
A brain tumor is an intracranial solid neoplasm which is a tumor within the brain or 
the central spinal canal. Brain tumors are created by an abnormal and uncontrolled cell 
division. These tumors can be either malignant which means cancerous or benign (non- 
cancerous). In fact, the combination of different factors like the type of tumor, its size, its 
state of development, and its location can determine the tumor threat level (Barrow 
Neurological Institute, 2013).  
The incidence rate in the United States for primary brain and nervous system tumors 
in 20 years old adults or older is estimated to be 27.4 per 100,000 persons (Ostrom, 
Gittleman, & Farah, et al., 2013). Approximately one-third of tumors in these different cases 
are malignant and the remainder is benign or even borderline malignant (Kohler, Ward, & 
McCarthy, et al., 2011; Ostrom, Gittleman, & Farah, et al., 2013). 
1.1.2. Classification  
According to the World Health Organization (WHO), primary brain tumors are 
classified according to their histological characteristics and cellular origin. Thus, WHO 
classifies primary brain tumors into five different classes which include, lymphomas and 
hematopoietic neoplasms, tumors of the cranial and paraspinal nerves, neuroepithelial 
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tumors, tumors of the meninges, and an important fifth class that includes germ cell tumors 
and tumors of the sellar region (Louis, Ohgaki, Wiestler, & Cavenee, 2007). Gliomas, which 
belong to the neuroepithelial brain tumors, include oligodendroglioma, astrocytoma, 
ependymoma, mixed glioma, and glioblastoma (CBTRUS, 2011). In addition, gliomas are 
categorized based on their grade, so they can be either low-grade gliomas or high-grade 
gliomas. Low grade gliomas are well-differentiated, benign, and carry better prognosis, 
whereas high-grade gliomas are malignant and carry worse prognosis. Approximately, 
gliomas make about 30% of brain and central nervous system tumors and about 80% of all 
malignant brain tumors (Goodenberger, & Jenkins, 2012). 
1.2. Astrocytoma 
Astrocytoma develops from glial cells called astrocytes. They may occur in different 
parts of the brain and most commonly in the cerebrum (Ohgaki, & Kleihues, 2009). The 
World Health Organization (WHO) classified astrocytoma according to a grading scheme 
which is based on the presence of specific characteristics such as mitosis, necrosis, atypia, 
and endothelial proliferation. The four grades include: grade I which is Pilocytic 
astrocytoma, grade II (low-grade diffuse astrocytoma), grade III (Anaplastic astrocytoma), 
and grade IV (Glioblastoma multiforme, GBM) (Ohgaki, & Kleihues, 2009).  
In addition, grade II astrocytoma are well differentiated tumors that seldom grow but 
show an intrinsic susceptibility for diffuse infiltration of the different neighboring brain 
structures. Thus, Grade III and IV astrocytoma are considered malignant accounting for the 
majority of the patients’ mortality (Watanabe, et al., 2003).  
1.3. Cell cycle is controlled by PI3Kinase/Akt pathway  
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 A pro-survival signaling pathway in a cell includes the “Phosphatidylinositol 3-
kinase (PI3-K)/Akt signaling pathway”. Cellular stimuli and toxic insults activate this 
signaling pathway. In fact, PI3K/Akt signaling pathway regulates different cellular functions, 
which include proliferation, apoptosis, translation, growth, and cell cycle progression 
(Maddika, et al., 2007).  This family of lipid kinases catalyzes the phosphorylation of 
phosphoinositides (Dbouk & Backer, 2010).  
 PI3Ks are classified into three different classes depending on their sequence 
homology and the specificity of their substrates. Thus, RTKs or Receptor Tyrosine Kinases 
and the GPCRs or G-protein coupled receptors are upstream of Class I PI3Ks which 
phosphorylate PI(4,5)P2 to produce PI(3,4,5)P3 that recruits proteins which includes Pleckstrin 
homology (PH) domain. In fact, the two main classes of PI3Ks are Class IA and Class IB. The 
first class includes heterodimer PI3Ks of P110α catalytic subunit and with regulatory subunits 
including P85, P50 and P55. However, Class IB PI3Ks include dimers with a P110 catalytic 
subunit and regulatory subunits that are P101 and P87. This classification allows Class IA of 
PI3Ks to be downstream of receptor tyrosine kinases (RTKs) and Class IB of PI3Ks to be 
downstream of G-proteins coupled receptors (GPCRs) (Dbouk & Backer, 2010). Therefore, 
this will allow the activation of different intracellular proteins included in many signaling 
pathways to regulate cell proliferation and motility (Vivanco & Sawyers, 2002).  
 Akt is one of the main downstream targets of Phosphatidylinositol 3-kinase. 
When the PH domain of Akt binds to the PI3K phospholipid products, Akt will be 
translocated into the plasma membrane. Hence, at this stage, Akt is activated by the 
phosphorylation of upstream kinases mTOR and PDK-1. Thus, upon its activation, Akt 
activates many proteins that are included in different cellular responses such as cell survival 
(Dugourd et. al, 2003).  
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Figure 1: Akt promotes cell survival and prolifiration.  Downstream of PI3K, the 
activated Akt phosphorylates and activates cytosolic different effectors which lead to cell 
growth and proliferation.  Source: (Echeverria & Sellers, 2008). 
 
1.4. Glioma Invasion  
Glioma invasion into parts of the brain is a multistep process which consists of a 
number of steps that include integrated extracellular and intracellular interactions (Nakada, et 
al., 2007). First of all, glioma cells should detach from the original site which is the emerging 
tumor mass. Thus, the subsequent step is the binding of those cancer cells to the ECM, 
extracellular matrix. Then, degradation of the ECM is triggered by the secretion of matrix 
proteinases or activators of matrix proteinases from the glioma cells. These glioma cells 
migrate through creating a space which is formed by the degradation of the ECM to finalize 
the invasion process (Giese, et al., 2003).  
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1.4.1. Factors included in glioma invasion 
In order for the glioma cell to detach, downregulation of some adhesion molecules 
involving E-cadherin and NCAM, neural cell adhesion molecules is required 
(Teodorczyk & Martin- Villalba, 2010). In fact, homophilic binding is mediated by 
NCAM which corresponds to the superfamily of glycoprotein immunoglobulin 
receptors. Also, as the astrocytic tumors progresses, the NCAM expression decreases. 
Another necessity for the detachment requires the cadherin switch proposed to occur 
during the conversion from a benign tumor to a malignant invasive tumor. This shift 
includes E-cadherin downregulation and N-cadherin upregulation (Teodorczyk & 
Martin- Villalba, 2010).  The metastatic and invasive properties of cells are directly 
related to their adhesive state. This mechanism is reflected by the increase of cells’ 
adhesion to mesenchymal cells and a decrease of adhesion to their neighboring epithelial 
cells (Hulit, et al., 2007). In fact, CD44, an adhesion molecule that is a main part of the 
initiation of invasion is upegulated in human gliomas (Ranuncolo, et al., 2002). This 
adhesion molecule is a transmembrane glycoprotein and also a member of the 
immunoglobulin receptor superfamily.   
 
The next step involved in invasion is the attachment to the ECM through 
transmembrane proteins called integrins which form focal adhesions. These focal 
adhesions are known to be mature focal complexes which represent integrin receptor 
aggregation on the cell surface (D'Abaco & Kaye, 2007).  Furthermore, many classes of 
proteases such as matrix metalloproteinases (MMPs) specifically MMP-2, MMP-9, and 
membrane-type MMP (MT-MMP) and ADAMs (a disintegrin and metalloproteinase) 
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are responsible for the ECM remodeling. Plasmin, which is included as a leading factor 
in this multistep process, is needed to activate MMP protoenzymes. Moreover, the 
generation of plasmin from plasminogen is directly related to urokinase (uPA) which is 
activated by attaching to its receptor uPAR (Ranuncolo, et al., 2002). 
Finally, the effective migration of glioma cells through the ECM finalizes the 
invasion process.  
 
Figure 2: Process of glioma invasion. Glioma invasion involves the detachment from 
the original site, attachment to ECM, degradation of ECM, and cell migration. 
(Source: Nakada, et al., 2007) 
1.5. Cell Motility 
Various biological processes such as inflammation, cancer cell invasion and 
metastasis, tissue regeneration involve cell migration (Leonithas et. al, 2014). Cell 
motility usually occurs in response to chemoattractants or different growth factors 
present in the ECM. This action is called chemotaxis (Lauffenburger & Horwitz, 1996). 
Cells move in a polarized manner, and undergo actin polymerization which allows it to 
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extend an important actin- rich protrusion, most likely as lamellipodia or filopodia, in 
the direction of the chemoattractant (Bailly, Condeelis, & Segall, 1998). There are steps 
that follow in order to achieve the motility cycle that involve formation of the adhesion 
structures which stabilize the protrusion, progression of a contractile force that transfers 
the cell body to the forward direction, liberation of the adhesion structures at the cell end 
and retraction of the cell to the direction of the movement (Condeelis, et al., 2001). 
Thus, the Rho family of GTPases plays an important role in regulating the cell motility 
cycle by reorganizing the actin cytoskeleton (Condeelis, et al., 2001).  
 
Figure 3: The cell motility cycle. For cell motility to be achieved, a cell must protrude, 
form focal adhesions in order to stabilize the protrusion, disassemble the old adhesion in 
the tail, and contract so the cell body can move forward. Source: (Alexander & 
Chernoff, 2003).  
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1.6. Metformin  
1.6.1. Medical Uses 
 Metformin, known as (N, N-dimethylbiguanide)  is an oral anti-hyperglycemic 
agent in the biguanide class which lowers blood glucose concentrations and has been 
used to treat type 2 diabetes mellitus (Miyoshi, et al., 2013; Saito, et al., 2013). 
Metformin was well-known as a glucose-lowering drug and came to be available for 
human intake in UK (Witters, 2001). Metformin became of international interest; in 
1995, it was FDA approved in the US (Kourelis & Siegel, 2011). Metformin is highly 
used in polycystic ovary syndrome (PCOS), premature puberty, and non-alcoholic fatty 
liver disease (NAFLD) (Lord, Flight, & Norman, 2003; Marchesini, et al., 2001; 
Ibáñez, et al., 2006). 
 
1.6.2. Mechanism of action  
  Metformin primarily decreases hyperglycemia by suppressing glucose 
production by the liver (Kirpichnikov, McFarlane, & Sowers, 2002). In addition, 
metformin increases insulin sensitivity, decreases the absorption of glucose from the 
gastrointestinal tract, and enhances the peripheral glucose uptake by inducing the 
phosphorylation of GLUT4 enhancer factor (Collier, et al., 2006). Thus, metformin, 
which is an insulin-sensitizing drug, is used to manage type2 diabetes and to improve 
glycemic control in insulin resistant patients. Inhibiting the secretion of hepatic glucose 
which decreases hyperinsulinemia is the important metabolic action of metformin. In 
fact, this mechanism is conveyed by the activation of AMPK, an energy sensing AMP-
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activated protein kinase in hepatocytes via the LKB1, the liver kinase B1 signaling 
pathway (Karnevi, Said, Andersson & Rosendahl, 2013). 
 Moreover, metformin shows an important antiproliferative action on many 
cancer cells, including pancreatic, colon, lung, breast, ovarian and prostate cancer cell 
lines. Furthermore, in vitro research proposed that metformin prevents the growth of 
cancer cells by activating AMPK which is adenosine monophosphate protein kinase, 
rendering mammalian target of rapamycin (mTOR) inactive, and diminishing the 
activity of S6K1 which is an mTOR effector (Sarfstein et. al, 2013).  Therefore, 
metformin induces the AMPK- dependent inhibition of the IGF-1/insulin pathway. This 
inhibition is done through the phosphorylation of the IRS-1 at Ser794 residue, which, in 
contrast with the IGF1R/R- mediated phosphorylation, promotes the decrease in IRS-1, 
AKT, and mTOR1 activation (Figure 4). It’s valuable to highlight that metformin 
disrupts the important cross-talk between the GPCR and IGF-1/insulin pathways and 
blocks ERK1/2 through the LKB1-mediated suppression of mTOR1 (Pierotti et. al, 
2013). 
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Figure 4: Action of Metformin on the IRS-1 and G protein-coupled receptor 
(GPCR) pathways. Explained in the above section. 1.7.2. Source: (Pierotti et. al, 
2013). 
 
1.7. Purpose of the study 
In the current study, we aim to investigate the role of metformin on the motility and 
the proliferation of brain cancer cell lines. As a first step, we studied metformin’s effect 
on the cellular proliferation by treating the cells with the drug for 24 hours and 
performing different assays. Then, we studied the effect of metformin on cellular 
motility. Finally, we examined the possible effect of metformin on the PI3K activity 
through its effect on the activity of the anti-apoptotic protein AKT.  
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Chapter II 
MATERIALS & METHODS 
 
2.1 . Cell Culture 
Human astrocytoma cell line SF268 was cultured in DMEM medium 
supplemented with 10% FBS and 100U penicillin/streptomycin at 37°C and 5% CO2 in 
a humidified chamber. 
2.2 . Antibodies and reagents 
The following primary antibodies were used in the study: rabbit monoclonal 
antibody against pan-Akt (Abcam Inc, Cambridge, UK) and rabbit monoclonal antibody 
against Akt1 phosphorylated at S473 (Abcam Inc, Cambridge, UK) purchased from 
Abcam.  
Furthermore, anti-rabbit HRP- conjugated secondary ntibody was obtained from 
Promega (Promega, CO., Wisconsin).  
Collagen was purchased from Invitrogen. Metformin (1, 1-dimethylbiguanide 
hydrochloride) was purchased from Sigma-Aldrich. 500mg pill was dissolved in 1L 
PBS.   
2.3.  Cell proliferation reagent (WST-1) 
Cells were seeded in 96-well plates (growth area: 0.6cm2) at a concentration of 
1x10
5
cells/ml. Depending on the experiment, cells were treated with metformin 
(2.5mM) with a control (only media). Following treatment period, 10μl of Cell 
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Proliferation Reagent (WST-1; Roche, Germany) was added to each well. The plates 
were incubated in a humidified incubator (37°C) in 95% air and 5% CO2 for 2 hours. 
WST-1 is a tetrazolium salt that on contact with metabolically active cells is cleaved to 
produce formazan dye by mitochondrial dehydrogenases. Quantitation of formazan is 
done colorimetrically at 450nm. The absorbance of the each blank well was subtracted 
from the corresponding sample well. The results were normalized to the corresponding 
controls, and the percent of cell proliferation was reported. 
 
2.4.  Wound healing assay 
Cells were grown to confluence on culture plates and a wound was made in the 
monolayer with a sterile pipette tip. After wounding, the cells were washed to remove 
debris and new medium was added. Phase-contrast images of the wounded area were 
taken at 0 and 24 hours after wounding. Wound widths were measured at 12 different 
points for each wound, and the average rate of wound closure was calculated in µm/hr. 
 
2.5.  Western blotting 
Cell lysates were prepared by scraping the cells in a sample buffer consisted of 
4% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 0.125 
M Tris-HCl at a pH of 6.8. The resulting lysates were boiled for 5 minutes. Protein 
samples were separated by SDS-PAGE on 8% or 15% gels and transferred to PVDF 
membranes overnight at 30V. The membranes were then blocked with 5% non-fat dry 
milk in PBS containing 0.1% Tween-20 for 1 hour at room temperature and incubated 
with primary antibody at a concentration of 1:500 for 2 hours at room temperature. After 
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the incubation with the primary antibody, the membranes were washed and incubated 
with secondary antibody at a concentration of 1:1000 for 2 hour at room temperature. 
The membranes were then washed, and the bands visualized by treating the membranes 
with western blotting chemiluminescent reagent ECL (GE Healthcare). The results were 
obtained on an X-ray film (Agfa Healthcare). The levels of protein expression were 
compared by densitometry using the ImageJ software. 
2.6.  Invasion Assay  
Cells were treated with metformin and invasion assay was performed after 48hrs 
treatment using the collagen-based invasion assay (Millipore) according to 
manufacturer’s instructions. In short, 24hrs before doing the invasion assay, cells were 
starved with serum-free medium. Then, cells were harvested, centrifuged and 
resuspended in quenching medium (media without serum). Then, cells were brought to a 
concentration of 0.6x106cells/mL. By this time, inserts were prewarmed with 300µL of 
serum free medium for 30min at room temperature. After rehydration, 250µL of media 
was removed from inserts and 250µL of cell suspension was added. Then, inserts were 
placed in a 24-well plate, and 500µL of complete media (with 10% serum) was added to 
the lower wells. Plates were incubated for 24hrs at 37°C in a CO2 incubator. Following 
incubation period, inserts were stained for 20min at room temperature with 400µL of 
cell stain provided with the kit. Stain was then extracted with extraction buffer (also 
provided). 100µL of extracted stain was then transferred to a 96-well plate suitable for 
colorimetric measurement using a plate reader. Optical Density was then measured at 
560 nm. 
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2.7. Adhesion Assay  
96-well plates were covered with collagen using Collagen Solution, Type I from rat 
tail (Sigma) overnight at 37°C and then washed with washing buffer (0.1% BSA in 
DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37°C in a CO2 
incubator for 1 hour. Then, Plates were washed and put on ice. At the same time, cells 
were trypsinized and counted to 4x105cell/mL. 50µL of the cells were then added in 
each well and incubated at 37°C in a 5% CO2 incubator for 30 minutes. Plates were then 
shaken and washed for 3 times. Fixation of the cells took place with 4% 
paraformaldehyde at room temperature for 10 minutes. Cells were washed and stained 
with crystal violet (5mg/mL in 2% ethanol) for 10 minutes. After staining, plates were 
washed very well with water, and left aside to dry completely. Crystal violet was 
solubilized by incubating the cells with 2% SDS for 30 minutes. The absorption of the 
plates was read at 550nm using ELISA. 
2.8. Statistical Analysis  
All the results reported represent average values from three independent 
experiments. All error estimates are given as ± SEM. All the results showed statistical 
significance with a p-value ≤ 0.05. 
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Chapter III 
RESULTS 
 
3.1. Metformin treatment decreases astrocytoma cells viability 
We wanted to study the effect of metformin on astrocytoma cancer cell viability. First, 
we treated the cells with metformin with different concentrations and then proliferation 
assay was performed using the cell proliferation reagent (WST-1). Thus, WST-1 reagent 
showed around 50% decrease in cellular proliferation of cells treated with metformin at 
2.5mM concentration (Figure 5).  
 
 
Figure 5: Treatment with metformin decreases cell viability. Cells were treated with 
metformin over a range of different concentrations.  The duration of the treatment was 
24hrs. Using WST-1 reagent, 50% decrease in the cellular proliferation was observed at 
2.5mM concentration. Data are the mean -/+ SEM from 3 experiments.  
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3.2. Metformin decreases cellular motility  
 
After we proved that metformin has a main role in the proliferation of cancer 
cells, we wanted to further investigate the effect of this same drug in 2D motility. Hence, 
we treated the cells with metformin and studied its effect using wound healing assay. 
Thus, results showed a decrease in motility of around four and a half folds in terms of 
wound closure in the cells with metformin treatment at 2.5mM (0.22μm/hr) with respect 
to the control cells (1μm/hr) (Figure  6 A&B). 
 
Figure 6: Metformin inhibits cellular motility. Cells (SF 268) were treated with 
metformin. A) Cells from the control and treatment were grown in plates and formed 
monolayer then wounded and pictured directly (upper micrographs). After 24 hours, 
pictures were imaged at the same frame (Lower micrographs). B) Quantitation for A. 
Width of single wound was measured at 12 distinct points, and average rate of wound 
closure was calculated in µm/h. Data are the mean -/+ SEM from 3 different wound 
healing experiments. The results were significant with p=0.02. 
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3.3.  Metformin treatment decreases cellular invasion 
 
After we proved that metformin treatment has a role in astrocytoma cancer cell 
proliferation, we next wanted to examine the effect of metformin treatment on cellular 
invasion. We used an in vitro collagen-based invasion assay through which FBS was 
used as a chemoattractant. The results showed around 30% decrease in cell invasion in 
the cells treated with metformin at 2.5mM compared to the control cells (Figures 7A-B).  
 
 
Figure 7: Metformin treatment decreases cellular invasion. A. Representative 
micrographs that show invaded cells on the bottom side of the membrane which is 
stained with the cell stain crystal violet according to the assay instructions. B. Extraction 
of cell stain was done and colorimetric measurements using ELISA were taken at 
560μm. Data is measured in arbitrary units and normalized to the control. Data are the 
mean -/+ SEM from 3 experiments.  
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3.4.  Metformin treatment increases cellular adhesion to collagen  
 
Since metformin treatment showed a decrease in the cellular motility, we wanted to 
further investigate the effect of this treatment on the adhesion of these astrocytoma 
cancer cells to collagen, which is an important component of the ECM. The results 
showed around a 35 percent increase in the adhesion of these cells with treatment as 
compared to the control cells (Figures 8 A-B). 
 
 
 
Figure 8: Metformin treatment increases cellular adhesion to collagen. A. 
Representative micrographs of cells that were fixed and stained with crystal violet to 
detect adhesion. B. Quantitation of the micrographs. Crystal violet was solubilized. 
Absorption was taken at 550μm using ELISA. Data is measured in arbitrary units and 
normalized to the control. Data are the mean -/+ SEM from 3 experiments. The results 
were significant with p=0.02.  
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3.5. Metformin treatment inhibits the activity of anti-apoptotic 
protein Akt  
 
Another important aspect was to study the effect of Metformin treatment on 
cellular proliferation through its effect on the activity of the anti-apoptotic protein 
AKT. Cells were treated with metformin for 24 hours. Then, cells were lysed and 
the total proteins were extracted. Thus, immunoblotting was done using a 
phosphospecific antibody which is anti-AKT antibody. Results showed that the 
phosphorylation of the AKT protein is partially inhibited (31%) upon Metformin 
treatment at 2.5mM (Figure 9 A&B).  
 
 
 
Figure 9: Metformin treatment inhibits the activity of anti-apoptotic protein Akt. 
Cells were plated and treated with metformin for 24 hours. A. Cells were lysed and 
then immunoblotted by western blotting analysis for P-Akt (Lower gel) and for Akt 
(Upper gel). As seen in the lower gel, metformin led to the inhibition of phosphorylation 
of Akt. B. The bands in the above gels were quantified using the ImageJ software, and 
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then were normalized to the control. Data are the mean -/+ SEM from 3 different 
experiments. The results were significant with p=0.03. 
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CHAPTER IV 
DISCUSSION 
 
Metformin, 1, 1 dimethylbiguanide hydrochloride, is a universally used anti-
diabetic agent which has been proved to perform an anti-cancerous activity in many 
tumor models (Levesley, et. al, 2013).  In our study, an inclusive characterization of 
metformin in astrocytoma cancer cells is provided, regarding its effect on the viability 
and proliferation of cells, motility and invasion, as well as its role on the expression of 
the anti-apoptotic protein Akt. 
 
 We examined an in vitro model of astrocytoma cancer cell line i.e. SF-268, to 
initially look at the effect of metformin on cellular proliferation and viability. In fact, 
using the WST-1 proliferation assay, results showed that the treatment of metformin in 
this cell line led to a decrease in cellular viability. These results were consistent with a 
recent study which showed that metformin diminishes cell viability and triggered 
apoptotic morphological alterations in the T98G glioblastoma multiforme cells using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Ucbek 
et.al, 2014). In addition, another study showed that 2.5 mM of metformin, which is the 
same concentration that we used, suppresses 46% U87MG proliferation, and inhibits 
92% T98G and 99% U251 proliferation respectively (Kennedy, et.al, 2013). 
Furthermore, another study showed that metformin resulted in a strong inhibition of the 
cellular proliferation in all gastric cancer cell lines (Kato, et.al, 2012). 
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 After proving that metformin has an important role in decreasing the cellular 
proliferation and viability of astrocytoma cancer cells, we then needed to study the effect 
of metformin on the 2D cell motility. Indeed, the treatment of metformin in the SF-268 
cell line inhibited cell motility by 80% at 2.5mM concentration using wound healing 
assay. This was consistent with previous studies in which treatment with metformin 
repressed the growth and migration of many cancer cell lines including pancreatic, 
breast, renal cell, colon, lung, ovarian, glioma, and prostate (Isakovic, et.al, 2012; 
Zakikhani, et.al, 2006; Rattan, et.al, 2011) . 
 To further examine the suppression of the 2D cell motility caused by metformin 
treatment, an adhesion assay was performed, which as expected indicated a foremost 
increase in the steadiness and adhesion of the cells to collagen upon metformin 
treatment. This means metformin is keeping RhoA active, preventing the dissolution of 
focal adhesions required for cells to move. Also, this increase in adhesion could have 
prohibited the retraction of the tail, which we greatly suspect is the major incident that 
inhibited cell motility. This increase in adhesion was consistent with previous work in 
our lab on astrocytoma and breast cancer cell lines through STARD13, a Rho GAP, 
through which the leading active RhoA and StarD13 knockdown led to the formation of 
greater focal adhesions (Khalil et. al, 2011; Hanna et. al, 2012). Hence, this hardens our 
results with metformin treatment, where we normally have an increase in the activity of 
RhoA, and thus stimulating cellular adhesion. 
 After showing the mechanism through which metformin might influence the 
random 2D cellular motility, it was exciting to us to investigate its effect on the 3D 
motility, which means cellular invasion. We treated the cells with metformin and 
examined a collagen-based trans-well invasion assay. Knowing that metformin clearly 
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inhibited the cellular motility in 2D, it was expected that it would also suppress cellular 
invasion. Thus, our expectation was in its place, by which metformin treatment 
decreased cellular invasion, regardless of the fact that metformin increases cellular 
adhesion.  Moreover, previous study supported our results by showing a decrease in 
cellular invasion in many cell lines. Thus, in vitro approaches have shown that 
metformin inhibits the cellular invasion in melanoma (Cerezo, et.al, 2013). Another 
study has shown that Metformin strongly blocked U251 brain cancer cell invasion (Gao, 
et.al, 2013). Furthermore, another study has shown that metformin decreases the cellular 
invasion and migration of ovarian cancer cells (Wu, et.al, 2012). 
 After proving that metformin has an important and direct effect on the 
proliferation and motility of astrocytoma cells, we wanted to further investigate the 
possible effect of metformin on the activity of the anti-apoptotic protein AKT. Our 
results showed that metformin inhibits the phosphorylation of Akt, as by western blot 
analysis, which means it’s possibly inhibiting the PI3K activity. These results were 
consistent with previous studies which showed that the effects of Metformin in 
glioblastoma cells were correlated with a potent inhibition of Akt-dependent cell 
survival pathway (Würth, et.al, 2013). So, our data showed that metformin inhibits PI3K, 
which means Rac is being inhibited.  This is consistent with previous work which showed 
that Rho and Rac works in an antagonistic manner (Shoval & Kalcheim, 2012). 
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CONCLUSION 
 
In our present study, we have designated the role of metformin in astrocytoma 
cancer cell proliferation and motility. Our results revealed that metformin deleteriously 
affects cellular viability and proliferation. Metformin has different roles in the 2D and 
3D motility. Metformin treatment inhibited the 2D cell migration. However, this effect 
of metformin has increased cellular adhesion to collagen but decreased cellular invasion. 
Last but not least, metformin treatment inhibited the phosphorylation of Akt, which 
possibly means blocked the PI3K activity.   
Auxiliary experiments are still to be performed to further investigate the role of 
Metformin on the viability and proliferation by flow cytometry. Other supplementary 
studies include finding the possible interaction of metformin with Rac1, Rho, and 
CDC42, and their influence on migration and invasion of brain cancer cells by 
preforming pull down assay. 
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